Equities

Orchid Pharma Ltd

ORCHPHARMA:NSI

Orchid Pharma Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (INR)1,401.55
  • Today's Change30.65 / 2.24%
  • Shares traded79.85k
  • 1 Year change+168.83%
  • Beta3.4160
Data delayed at least 15 minutes, as of Sep 20 2024 10:41 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 18-Jul-24
  • 15-Aug-24
  • 12-Sep-24
Select bar for recommendation details.
Recommendations12-Sep-24
Buy2
Outperform1
Hold0
Sell0
Strong Sell0

Share price forecast in INR

The 3 analysts offering 12 month price targets for Orchid Pharma Ltd have a median target of 1,641.00, with a high estimate of 1,650.00 and a low estimate of 1,285.00. The median estimate represents a 19.70% increase from the last price of 1,370.90.
High20.4%1,650.00
Med19.7%1,641.00
Low-6.3%1,285.00

Dividends

Historical dividend information is not available for Orchid Pharma Ltd.
Div growth (TTM)--
More ▼

Earnings history & estimates in INR

On Feb 08, 2024, earnings of 6.18 per share.
Average growth rate+51.29%
Orchid Pharma Ltd reported annual 2024 earnings of 19.06 per share on May 24, 2024.
Average growth rate-37.52%
More ▼

Revenue history & estimates in INR

Orchid Pharma Limited had 1st quarter 2025 revenues of 2.44bn. This bettered the 2.26bn consensus of the 2 analysts covering the company. This was 10.80% above the prior year's 1st quarter results.
Average growth rate-9.42%
Orchid Pharma Limited had revenues for the full year 2024 of 8.19bn. Last year the company did not report any revenues.
Average growth rate-3.27%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.